Ramos, C., Montaño, E., Reyes-López, A., Lemus, F., Pacheco, M., Hernandez, G., & Lemus, A. (2019). Economic evaluation of lenalidomide (Revlimid®) for the treatment of mielodysplastic syndrome with 5q deletion at low/intermediate-1 risk: Evaluación Económica de Lenalidomida (Revlimid®) Para el Tratamiento Del Síndrome Mielodisplásico Con Deleción 5q de Riesgo Bajo/Intermedio-1. Global and Regional Health Technology Assessment, 4(1), 133–140. https://doi.org/10.33393/grhta.2017.387